Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer

Chest

Volumn 128, Issue 3, 2005, Pages 1453-1460

  Cheng, Tian Lu ^a   Chang, Mei Yin ^a   Huang, Sung Yu ^b   Sheu, Chau Chyun ^a   Kao, Eing Long ^a   Cheng, Yu Jen ^a   Chong, Inn Wen ^a,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b Sung Hua Gene Co Ltd   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

c met; Circulating c met; Non small cell lung cancer; Real time polymerase chain reaction

Indexed keywords

LIGAND; MESSENGER RNA; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENDER; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; MULTIVARIATE ANALYSIS; ONCOGENE; ONCOGENE C MET; PATHOLOGY; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 24944468127     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.3.1453     Document Type: Article

References (36)

1. Pantel K, Izbicki JR, Angstwurm M, et al. Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res 1993; 53:1027-1031
2. Passlick B, Izbicki JR, Kubuschok B, et al. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. J Clin Oncol 1994; 12:1827-1832
3. Pantel K, Izbicki J, Passlick B, et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 1996; 347:649-653
4. Maruyama R, Sugio K, Mitsudomi T, et al. Relationship between early recurrence and micrometastases in the lymph nodes of patients with stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg 1997; 114:535-543
5. Mori M, Mimori K, Inoue H, et al. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1995; 55:3417-3420
6. Noguchi S, Aihara T, Motomura K, et al. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase- polymerase chain reaction: comparison between MUC1 mRNA and keratin 19 mRNA amplification. Am J Pathol 1996; 148:649-656
7. Noguchi S, Aihara T, Nakamori S, et al. The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer 1994; 74:1595-1600
8. Merkelbach-Bruse S, Wardelmann E, Behrens P, et al. Current diagnostic methods of HER-2/neu detection in breast cancer with special regard to real-time PCR. Am J Surg Pathol 2003; 27:1565-1570
9. Sakakura C, Takemura M, Hagiwara A, et al. Overexpression of dopa decarboxylase in peritoneal dissemination of gastric cancer and its potential as a novel marker for the detection of peritoneal micrometastases with real-time RT-PCR. Br J Cancer 2004; 90:665-671
10. Pantel K, Von Knebel Doeberitz M. Detection and clinical relevance of micrometastatic cancer cells. Curr Opin Oncol 2000; 12:95-101
11. Schuster R, Max N, Mann B, et al. Quantitative real-time RT-PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers. Int J Cancer 2004; 108:219-227
12. Thomasson M, Hedman H, Guo D, et al. LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT-PCR and immunohistochemical analysis. Br J Cancer 2003; 89:1285-1289
13. Guller U, Zajac P, Schnider A, et al. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 2002; 236:768-775
14. Ady N, Morat L, Fizazi K, et al. Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients. Br J Cancer 2004; 90:443-448
15. Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984; 311:29-33
16. van der Voort R, Taher TE, Derksen PW, et al. The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. Adv Cancer Res 2000; 79:39-90
17. Ichimura E, Maeshima A, Nakajima T, et al. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996; 87:1063-1069
18. Takanami I, Tanana F, Hashizume T, et al. Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers. Oncology 1996; 53:392-397
19. McDoniels-Silvers AL, Nimri CF, Stoner GD, et al. Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. Clin Cancer Res 2002; 8:1127-1138
20. Olivero M, Rizzo M, Madeddu R, et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 1996; 74:1862-1868
21. Maulik G, Kijima T, Ma PC, et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002; 8:620-627
22. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111:1710-1717
23. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-159
24. Cox D. Regression models and life tables (with discussion). JR Stat Soc 1972; 34:187-200
25. Tsao MS, Liu N, Chen JR, et al. Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer 1998; 20:1-16
26. Carbone DP, Mitsudomi T, Chiba I, et al. p53 imrnunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer: a preliminary report of LCSG 871. Chest 1994; 106:3778-3818
27. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323:561-565
28. Lee JS, Yoon A, Kalapurakal SK, et al. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol 1995; 13:1893-1903
29. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329:690-694
30. Yu CJ, Shun CT, Yang PC, et al. Sialomucin expression is associated with erbB-2 oncoprotein overexpression, early recurrence, and cancer death in non-small-cell lung cancer. Am J Respir Crit Care Med 1997; 155:1419-1427
31. Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997; 15:2858-2865
32. Graziani A, Gramaglia D, dalla Zonca P, et al. Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger. J Biol Chem 1993; 268:9165-9168
33. Webb CP, Taylor GA, Jeffers M, et al. Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene 1998: 17:2019-2025
34. Kuba K, Matsumoto K, Date K, et al. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 2000; 60:6737-6743
35. Morotti A, Mila S, Accornero P, et al. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 2002; 21:4885-4893
36. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003; 63:7345-7355